title: Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles.
abstract: OBJECTIVE
  To investigate the efficacy and safety of intravaginal Crinone 8% (Columbia Research Laboratories, Miami. FL) versus IM progesterone for luteal phase support after IVF-ET.
  
  
  METHODS
  Prospective open trial with comparison to historical controls.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  Two hundred six women undergoing IVF-ET.
  
  
  METHODS
  One hundred patients received Crinone vaginal progesterone gel (90 mg once daily) and 106 patients received IM progesterone (50 mg once daily) beginning on the evening of oocyte retrieval.
  
  
  METHODS
  Pregnancy and miscarriage rates, and midluteal serum progesterone levels.
  
  
  RESULTS
  Positive beta-hCG pregnancy rates, clinical pregnancy rates per transfer, and ongoing pregnancy rates were similar for the Crinone and IM progesterone groups. Women who received Crinone had higher rates of biochemical pregnancy loss but lower rates of clinical pregnancy loss (i.e., spontaneous abortion) than women who received IM progesterone. Midluteal serum progesterone concentrations were significantly higher in the IM progesterone group (94.3+/-8.8 ng/mL versus 57.7+/-7.4 ng/mL). Several women who received Crinone had vaginal bleeding 11-13 days after oocyte retrieval.
  
  
  CONCLUSIONS
  For all age categories, positive beta-hCG and ongoing pregnancy rates were similar when Crinone or IM progesterone was given for luteal phase support in IVF-ET cycles, despite lower serum progesterone concentrations and higher rates of biochemical pregnancy loss with Crinone. Although the results of this study support the use of Crinone as an acceptable alternative for luteal support after IVF-ET, differences in bleeding patterns and rates of biochemical pregnancy loss demonstrate the need for a prospective randomized study.
authors.affiliation: Department of Obstetrics and Gynecology, The University of Texas Southwestern Medical Center, Dallas, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Chantilis
authors.forename: K M
authors.initials: KM
authors.lastname: Zeitoun
authors.forename: S I
authors.initials: SI
authors.lastname: Patel
authors.forename: D A
authors.initials: DA
authors.lastname: Johns
authors.forename: V A
authors.initials: VA
authors.lastname: Madziar
authors.forename: D D
authors.initials: DD
authors.lastname: McIntire
mesh_terms: D000282:Administration, Intravaginal; D003338:Corpus Luteum / Q000187:drug effects*; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro; D005782:Gels; D006801:Humans; D007273:Injections, Intramuscular; D011247:Pregnancy; D011256:Pregnancy Outcome; D011374:Progesterone / Q000627:therapeutic use*
chemical_list: D005782:Gels; D011374:Progesterone